CoChat

Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

CONTEXT: Levothyroxine monotherapy is the treatment of choice for hypothyroid patients because peripheral T4 to T3 conversion is believed to account for the overall tissue requirement for thyroid hormones. However, there are indirect evidences that this may not be the case in all patients. OBJECTIVE: To evaluate in a large series of athyreotic patients whether levothyroxine monotherapy can normalize serum thyroid hormones and thyroid-pituitary feedback. DESIGN: Retrospective study. SETTING: Academic hospital. PATIENTS: 1,811 athyreotic patients with normal TSH levels under levothyroxine monotherapy and 3,875 euthyroid controls. MEASUREMENTS: TSH, FT4 and FT3 concentrations by immunoassays. RESULTS: FT4 levels were significantly higher and FT3 levels were significantly lower (p<0.001 in both cases) in levothyroxine-treated athyreotic patients than in matched euthyroid controls. Among the levothyroxine-treated patients 15.2% had lower serum FT3 and 7.2% had higher serum FT4 compared to euthyroid controls. A wide range of FT3/FT4 ratios indicated a major heterogeneity in the peripheral T3 production capacity in different individuals. The correlation between thyroid hormones and serum TSH levels indicated an abnormal feedback mechanism in levothyroxine-treated patients. CONCLUSIONS: Athyreotic patients have a highly heterogeneous T3 production capacity from orally administered levothyroxine. More than 20% of these patients, despite normal TSH levels, do not maintain FT3 or FT4 values in the reference range, reflecting the inadequacy of peripheral deiodination to compensate for the absent T3 secretion. The long-term effects of chronic tissue exposure to abnormal T3/T4 ratio are unknown but a sensitive marker of target organ response to thyroid hormones (serum TSH) suggests that this condition causes an abnormal pituitary response. A more physiological treatment than levothyroxine monotherapy may be required in some hypothyroid patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0022552

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Free thyroid hormones and FT3/FT4 ratio frequency distribution. FT3 and FT4 serum levels and FT3/FT4 ratio distribution in 1,811 athyreotic patients under levothyroxine (L-T4) monotherapy. Shaded areas indicate the normal range (2.5–97.5 percentiles) calculated in 3,875 euthyroid controls. Vertical dotted lines indicate the median of the normal values. Percentages indicate the patients with values under or above the normal values.
Figure 1 Free thyroid hormones and FT3/FT4 ratio frequency distribution. FT3 and FT4 serum levels and FT3/FT4 ratio distribution in 1,811 athyreotic patients under levothyroxine (L-T4) monotherapy. Shaded areas indicate the normal range (2.5–97.5 percentiles) calculated in 3,875 euthyroid controls. Vertical dotted lines indicate the median of the normal values. Percentages indicate the patients with values under or above the normal values.CC BY · PubMed Central
Figure 2 Correlation between TSH and free thyroid hormones in euthyroid controls and in athyreotic patients. The correlation between TSH serum levels (log values) and FT3 and FT4 serum levels in 3,875 euthyroid controls (solid lines) and 1,811 athyreotic patients under levothyroxine monotherapy (dotted lines). The linear regression equations between FT4 and log TSH levels in the euthyroid controls and the levothyroxine (L-T4)-treated patients were y = 14.0−1.1x (95%: slope −1.4 to −0.74) and y = 16.1−2.01x (95% CI: slope −2.48 to −1.53), respectively. The same curve fitting analysis was used between FT3 and log-TSH levels and resulted in the following: y = 4.4−0.029x (95% CI: slope −0.128 to 0.063) for euthyroid controls and y = 3.84−0.575x (95% CI: slope −0.697 to −0.453) for L-T4-treated patients. R square and P values are reported in the graph.
Figure 2 Correlation between TSH and free thyroid hormones in euthyroid controls and in athyreotic patients. The correlation between TSH serum levels (log values) and FT3 and FT4 serum levels in 3,875 euthyroid controls (solid lines) and 1,811 athyreotic patients under levothyroxine monotherapy (dotted lines). The linear regression equations between FT4 and log TSH levels in the euthyroid controls and the levothyroxine (L-T4)-treated patients were y = 14.0−1.1x (95%: slope −1.4 to −0.74) and y = 16.1−2.01x (95% CI: slope −2.48 to −1.53), respectively. The same curve fitting analysis was used between FT3 and log-TSH levels and resulted in the following: y = 4.4−0.029x (95% CI: slope −0.128 to 0.063) for euthyroid controls and y = 3.84−0.575x (95% CI: slope −0.697 to −0.453) for L-T4-treated patients. R square and P values are reported in the graph.CC BY · PubMed Central
Figure 3 FT3/FT4 ratio in levothyroxine-treated athyreotic patients at different daily dose. Median FT3/FT4 ratio in levothyroxine (L-T4) treated athyreotic patients with respect to the administered daily dose of L-T4. The median and interquartile range in the euthyroid controls are indicated by the shaded area. The number of patients with a FT3/FT4 ratio lower than the 2.5 percentile of the euthyroid controls is indicated in the right panel.
Figure 3 FT3/FT4 ratio in levothyroxine-treated athyreotic patients at different daily dose. Median FT3/FT4 ratio in levothyroxine (L-T4) treated athyreotic patients with respect to the administered daily dose of L-T4. The median and interquartile range in the euthyroid controls are indicated by the shaded area. The number of patients with a FT3/FT4 ratio lower than the 2.5 percentile of the euthyroid controls is indicated in the right panel.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

32 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 307

Metadata

Authors
Gullo, D., Latina, A., Frasca, F., Le Moli, R., Pellegriti, G., & Vigneri, R.
Affiliations
University of Catania (IT)
Corresponding author
Gullo, Damiano
Venue
PLoS ONE
Published
2011-08-01
Volume
6
Issue
8
Pages
e22552
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2163820892
Cited by
307
References
32
Citations by year
2026: 14 · 2025: 25 · 2024: 20 · 2023: 26 · 2022: 27 · 2021: 25 · 2020: 31 · 2019: 30 · 2018: 20 · 2017: 18 · 2016: 20 · 2015: 18 · 2014: 12 · 2013: 9 · 2012: 10
FWCI
8.13
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Università di Catania
  • Associazione Italiana per la Ricerca sul Cancro
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
levothyroxine monotherapy, athyreosis, hypothyroidism, free triiodothyronine, free thyroxine, T3/T4 ratio, thyroid-stimulating hormone, euthyroidism
MeSH terms
Humans, Hypothyroidism, Immunoenzyme Techniques, Retrospective Studies, Thyroid Hormones, Thyrotropin, Thyroxine, Case-Control Studies, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients. https://app.cochat.ai/papers/10.1371/journal.pone.0022552
The paper
Gullo, D., Latina, A., Frasca, F., Le Moli, R., Pellegriti, G., & Vigneri, R. (2011). Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients. PLoS ONE. https://doi.org/10.1371/journal.pone.0022552

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.